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Admission blood glucose as a 
prognostic indicator in patients 
with acute myocardial infarction
ADMISSION 
BLOOD GLUCOSE
ABSTRACT
Objective: To investigate the utility of admission blood 
glucose for predicting major adverse cardiac events 
(MACE) during hospitalisation and 6 months’ post-
discharge in acute myocardial infarction (AMI) patients.
Methods and results: This study recruited 2878 AMI 
patients admitted to the Coronary Care Unit at R. K. 
Khan Hospital, Durban, South Africa, from 2002 - 2014. 
Demographic and clinical data stored in an electronic 
database were obtained from all patients. Admission 
blood glucose levels were sub-divided into 3 groups; low 
(<7.8), medium (7.8-10.9) and high (≥11) mmol/l.  The 
mean age of the study population was 57.18 ± 7 years of 
whom 65% were males. Self-reported diabetes was 
found in 59%, while 377 patients were diagnosed with 
diabetes based on HbA1c levels ≥6.5%, increasing the 
overall prevalence to 72% (n=2070). More patients were 
in the low admission blood glucose group (49%), medium 
group (16%), and high group (35%). The highest pre-
valence of MACE was seen in the high group (42%) 
compared to either the medium (39%) or low groups 
(26%; p<0.001), particularly for cardiogenic shock 
(p<0.001), cardiac failure (p<0.001) and death (p<0.001). 
Following multivariable logistic regression analyses of 
clinical and laboratory parameters associated with 
mortality, high admission blood glucose conferred a 
signifi cantly increased odds of mortality (p=0.001). The 
optimal cut-off admission blood glucose value as deter-
mined via the receiver operating characteristic curve 
for predicting in hospital and 6 months’ mortality was 
8.5mmol/l (AUC of 0.63) and 8.1mmol/l (AUC of 0.61) 
for MACE. 
Conclusions: This study shows that patients have 
multiple risk factors for AMI with diabetes playing a 
central role.  Although elevated admission blood glu-
cose is an important predictor for in hospital and short-
term MACE, the cut-off value for predicting MACE and 
mortality has only modest predictability and further 
research is required to improve the performance of 
these measures for routine clinical use.
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INTRODUCTION
Coronary heart disease (CHD) is a major cause of morbidity 
and mortality.(1) This is particularly important in people with 
diabetes because they are at increased risk of having CHD, 
and to have multi-vessel disease when it occurs.(2) Patients 
with both diabetes and acute myocardial infarction (AMI) are 
more likely to present with acute pulmonary oedema, and this 
increased incidence of heart failure occurs despite similar 
infarct sizes and left ventricular ejection fractions.(3,4) This 
observation suggests that the left ventricle in diabetes tolerates 
infarction poorly, irrespective of whether patients present with 
ST elevation myocardial infarction (STEMI) or non-ST eleva-
tion myocardial infarction (NSTEMI).
Another important consideration in patients with AMI is the 
positive association between the admission glucose values and 
mortality in patients with and without diabetes.(5) There appears 
to be a graded relationship between admission glucose levels 
with major adverse cardiac events (MACE) both during hospital 
admission and post discharge.(6) Although several mechanisms 
have been proposed as to why there are worse outcomes in 
patients presenting with AMI and higher glucose concentra-
tions on admission, it is still unclear whether high blood glucose 
is a marker for a sicker patient, as opposed to being causative 
for worse outcomes.
The optimal blood glucose cut-off value for the prediction of 
poor outcomes in AMI patients has not been determined. 
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Recommendations for glycaemic control comes from 3 popu-
lation groups, namely: critically ill patients from intensive care 
units, patients admitted with AMI, and general medical wards,(7,8) 
all of which have their limitations. This may explain why the 
optimal strategy for the management of hyperglycaemia in 
patients with and without diabetes admitted with AMI is largely 
unknown. However, there is general consensus around the 
following points, hypoglycaemia should be avoided, and blood 
glucose be maintained between 7 - 10mmol/l.(9)
In South Africa, the prevalence of CHD is high, especially 
amongst the Asian Indian population, who present with multiple 
risk factors for AMI, which probably explains why they present 
at an early age.(10) More importantly, in addition to other 
conventional risk factors, self-reported diabetes was found in 
46% of these patients with AMI. Considering the limited 
information available on glycaemic control on prognosis after 
an AMI, the present study therefore was undertaken to assess 
the utility of admission blood glucose for predicting MACE, 
both in hospital and 6 months’ post-discharge in AMI patients 
with and without diabetes. Furthermore, we also sought to 
determine the optimal cut-off admission blood glucose level for 
predicting poor outcomes in these patients.
METHOD
Study population
In this retrospective, observational study, we enrolled patients 
admitted to the Coronary Care Unit (CCU) at R. K. Khan 
Hospital, Durban, South Africa, with a diagnosis of AMI. The 
study was carried out according to the principles of the 
Declaration of Helsinki and approved by the local ethics com-
mittee. From 2002 - 2014, 3 142 patients were admitted to the 
CCU with a diagnosis of acute coronary syndrome, but only 
a total of 2 878 patients who fulfilled the inclusion criteria of 
AMI, and who had admission blood glucose results available, 
were enrolled into the study. Acute myocardial infarction was 
defined by prolonged chest discomfort, typical electrocardio-
graphic changes, and elevated cardiac troponin T (cTnT) levels, 
as outlined by the Joint European Society of Cardiology/
American College of Cardiology Committee.(11)
Clinical assessment
Demographic and clinical data stored in an electronic database 
were obtained from all patients and analysed. This data were 
collected in real time during patient’s admission to the CCU 
and all information was reviewed and validated by one of the 
co-authors. These included: age, gender, anthropometric 
measurements (body mass index and abdominal waist circum-
ference), and risk factors for CHD including a family history of 
vascular disease, clinical findings on admission, types of AMI, 
echocardiographic changes, treatment during hospitalisation 
and after discharge. A detailed description of complications 
encountered during hospital admission and 6 months’ post 
discharge such as ventricular arrhythmias, complete heart 
block, heart failure, cardiogenic shock, cerebrovascular acci-
dent (CVA), recurrence of angina/infarction, and death were 
recorded. 
In keeping with standard acute coronary syndrome guidelines, 
all patients were counselled and offered coronary angiograms, 
which were performed at another referral hospital. Patients 
were required to consent for both coronary angiography and 
cardiac revascularisation procedures such as percutaneous 
coronary intervention (PCI) and coronary artery bypass grafting 
(CABG), should there be a need to perform these procedures. 
This type of triage is necessary due to the large volume of work 
and the lack of adequate facilities in the public sector (only 1 
government-based hospital in the province of KwaZulu-Natal 
offers these specialised facilities). Consequently, only a limited 
number of patients underwent coronary angiography because 
the majority declined cardiac revascularisation. Patients who 
were eligible were thrombolysed with metalyse, as a revas-
cularisation therapy. 
Biochemical analyses
Blood samples were obtained intravenously from all subjects 
in the CCU immediately after hospital admission to quantify 
serum blood glucose concentrations and other biochemical 
measurements. Analyses were carried out using standard 
methods. 
Plasma glucose levels were measured using the Dimension EXL 
(Siemens Healthineers). Furthermore, we sub-divided admis-
sion blood glucose levels into 3 groups, low (<7.8 mmol/l), 
medium (7.8 - 10.9mmol/l) and high (≥11mmol/l), to assess 
whether an increasing degree of admission blood glucose levels 
was associated with an increased risk of MACE. The cut-off 
values for the 3 different categories of admission blood glucose 
was closely based on the 2-hour glucose values of the oral 
glucose tolerance test because the cut-off values for admission 
blood glucose, which discriminates between good and poor 
prognosis, varies over a wide range. Total cholesterol, triglyc-
erides (TGs), high-density lipoprotein cholesterol (HDL-C), 
and low-density lipoprotein cholesterol (LDL-C) were meas-
ured 48 hours after admission following a 9 - 12 hour over-
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night fast. Troponin T was measured on the Elecsys 2010 
(Roche Diagnostics) and the test was considered positive at 
a cut-off value >0.03 ng/ml.
Statistical analyses
Data were analysed using Stata 13.1 and R. Mean with standard 
deviation (SD) was used for continuous variables, or median 
with interquartile range (IQR) was used instead if the variable 
was skewed. Categorical data were presented using frequency 
tables. Association between categorical variables was assessed 
using the standard Pearson’s chi-square (x2) test. If expected 
cell count in the cross tabulation had fewer than 5 observations 
(sparse numbers) then the Fisher’s exact test was applied. The 
standard student’s t-test was used to compare the mean of 
continuous explanatory variables by dichotomous outcome 
classification. If the normality assumption was not upheld, then 
the non-parametric equivalent, namely the Wilcoxon rank-sum 
test, was used instead. Factors associated with mortality were 
assessed using bivariate and multivariable logistic regressions. 
This was performed to include the confounding influence of 
other variables (e.g. age, gender, etc.) in the multivariable 
adjusted estimates. Coefficients were exponentiated to present 
odds ratios (ORs) and 95% confidence intervals (CIs). Signi-
ficance in the adjusted models was assessed at p <0.05. Model 
fit (adequacy) was assessed using goodness of fit tests. The 
Youden index was used to identify the optimal breakpoints in 
blood glucose concentration in terms of its predictive capa-
bility for mortality and MACE. The discriminatory power was 
assessed using the AUC. An AUC ≥0.8 suggests good to 
excellent predictive capability. Sensitivity, specificity, positive 
predictive value, and negative predictive values based on the 
identified optimal cut-points were calculated. A p-value of 
<0.05 was taken as statistically significant.
RESULTS
The study cohort comprised 2 878 patients with AMI, of whom 
2 269 (79%) presented with STEMI (Table I). The mean age of 
the study population was 57.18 ± 11.47 years with a male 
preponderance (65%). Data were missing for certain variables 
such as abdominal gir th (n=440, 15%) and HbA1c (n=574, 
20%). Smoking (61%), self–reported diabetes (59%), hyper-
tension (53%), previous myocardial infarction (12%) and pre-
vious angina (12%) were the most commonly observed risk 
factors. Fifty-eight percent of the patients had a family history of 
coronary artery disease, diabetes (43%), hypertension (38%) 
and cerebrovascular disease (19%). Of the 41% of patients who 
did not present with a self-reported history of diabetes, HbA1c 
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TABLE I: Baseline characteristics of patients.
Characteristics  Summary n=2 878 (%)
Male 1 874 (65)
ST elevation myocardial infarction 2 269 (79)
Non-ST elevation myocardial infarction 609 (21)
Body mass index
Normal (≤25kg/m2) 1 249 (44)
Overweight (26 - 29kg/m2) 1 040 (36)
Obese (≥30kg/m2) 589 (20)
Risk factors 
Smoking 1 751 (61)
Self-reported diabetes 1 693 (59)
Newly diagnosed diabetes (HbA1C ≥6.5%) 377 (13)
Total diabetic population 2 070 (72)
    With nephropathy (eGFR <60mL/min/1.73m2) 586 (28)
    With retinopathy 363 (18)
Hypertension 1 516 (53)
Previous myocardial infarction 359 (12)
Previous angina 341 (12)
Family history of vascular disease
Coronary artery disease 1 657 (58)
Diabetes 1 238 (43)
Hypertension 1 104 (38)
Cerebrovascular disease 543 (19)
Medication at discharge 
ACEIs/ARBs 2 295 (80)
Beta blockers 1 770 (62)
Antiplatelets 2 862 (99)
Nitrates 2 847 (99)
Statins 2 738 (95)
Calcium antagonists 200 (9)
Diabetic treatment
    Oral hypoglycaemic drugs 1 169 (56)
    Insulin 516 (25)
    Insulin + oral hypoglycaemic drugs 385 (19)
Continuous variables 
Age (years) mean (SD) 57.18 ±11.47
Median (IQR)
Abdominal girth (cm) (n=2 438) 97 (90 - 105)
Female 99 (92 - 107)
Male 96 (89 - 104)
Heart rate (bpm) 82 (70 - 96)
Systolic BP (mmHg) 130 (111 - 150)
Diastolic BP (mmHg) 80 (70 - 91)
Biochemical data
Hemoglobin (g/dl) 14 (12.5 - 15.3)
Admission blood glucose (mmol/l) 7.8 (5.8 - 13.1)
HbA1c (%) (n=2 304) 6.9 (6 - 9)
Creatinine (μmol/l) 92 (79 - 112)
Troponin T (ng/ml) 2.14 (0.58 - 5.27)
Total cholesterol (mmol/l) 5.2 (4.3 - 6.02)
LDL cholesterol (mmol/l) 3.3 (2.59 - 4.02)
HDL cholesterol (mmol/l) 0.94 (0.79 - 1.13)
Triglycerides (mmol/l) 1.67 (1.17 - 2.43)
IQR = Interquartile Range; Oral hypoglycemic drugs included Metformin, 
Sulphonylureas, or combination of both.
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TABLE II: Baseline characteristics & outcomes of patients according to admission blood glucose.
Blood glucose
Characteristics
Low
<7.8mmol/l
n=1 424 (49%)
Medium
7.8 - 10.9mmol/l
n=456 (16%)
High
≥11mmol/l
n=998 (35%)
p-value
Age (years) Mean (SD) 55.46 (±11.73) 59.91 (±11.07) 58.39 (±10.89) <0.001
Gender 
Female 327 (23) 196 (43) 481 (48)
<0.001
Male 1 097 (77) 260 (57) 517 (52)
Non-ST elevation myocardial infarction 293 (21) 106 (23) 210 (21)
0.475
ST elevation myocardial infarction 1 131 (79) 350 (77) 788 (79)
Pharmacological reperfusion (n=871)            440 (40) 127 (36) 304 (39) 0.673
Body mass index
Overweight vs. normal BMI 491 (42) 169 (48) 380 (49) 0.003
Obese vs. non-obese 254 (18) 108 (24) 227 (23) 0.002
Risk factors 
Smoking 1 024 (72) 248 (54) 479 (48) <0.001
Hypertension 579 (41) 303 (66) 634 (64) <0.001
Diabetes 390 (27) 348 (76) 955 (96) <0.001
Previous angina 147 (10) 82 (18) 112 (11) <0.001
Previous myocardial infarction 166 (12) 70 (15) 123 (12) 0.114
Family history of vascular disease 
Hypertension 497 (35) 172 (38) 435 (44) <0.001
Diabetes 471 (33) 224 (49) 543 (54) <0.001
Coronary artery disease 802 (56) 284 (62) 571 (57) 0.078
Cerebrovascular disease 275 (19) 88 (19) 180 (18) 0.708
Killip class
1 1 327 (96) 396 (93) 814 (91) Ref
2 54 (4) 29 (7) 81 (9) <0.001
3 34 (2) 19 (4) 63 (7) <0.001
4 7 (0.5) 11 (3) 35 (4) <0.001
Major adverse cardiovascular events 370 (26) 175 (39) 415 (42) <0.001
Cardiac failure 142 (10) 92 (20) 231 (23) <0.001
Death 80 (6) 49 (11) 136 (14) <0.001
Cardiogenic shock 31 (2) 32 (7) 81 (8) <0.001
Recurrence of infarct 96 (7) 39 (9) 62 (6) 0.255
Recurrence of angina 57 (4) 25 (6) 46 (5) 0.392
Atrial fi brillation 34 (2) 15 (3) 23 (2) 0.498
Supraventricular tachycardia 11 (0.8) 5 (1) 8 (0.8) 0.795
Ventricular arrhythmia 48 (3) 19 (4) 44 (4) 0.397
Complete heart block 25 (2) 5 (1) 36 (4) 0.002
Cerebrovascular accidents 18 (1) 9 (2) 23 (2) 0.142
Coronary angiogram n=580 n=180 n=339 
Single vessel disease 151 (26) 34 (19) 72 (21) 0.160
Double vessel disease 165 (29) 55 (31) 91 (27)
Triple vessel disease 264 (46) 91 (51) 176 (52)
Coronary artery bypass graft 308 (53) 90 (50) 184 (54) 0.646
Percutaneous coronary intervention + stent 131 (23) 45 (25) 73 (22) 0.667
Continuous variables Median (IQR)
Heart rate (bpm) 80 (68 - 91) 84.5 (72 - 98) 86 (73 - 101) <0.001
Systolic BP (mmHg) 128 (110 - 149) 130 (111 - 150) 132 (114 - 153)   0.005
Diastolic BP (mmHg) 80 (70 - 91) 79 (70 - 90) 80 (70 - 91) 0.877
Abdominal girth (cm) (n=2 438) 95 (88 - 102) 99 (92 - 107) 99 (92 - 106) <0.001
Female 97 (89 - 105) 101 (93 - 108) 100 (93 - 107) 0.006
Male 95 (87 - 102) 98 (92 - 107) 98 (91 - 106) <0.001
Ejection fraction 54 (46 - 59) 54 (43 - 58) 52 (43 - 58) <0.001
IQR = Interquartile Range.                                                                                                                                                                       Table II continued overleaf
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levels were performed on admission in 930 subjects. An 
additional 41% (n=377) were diagnosed with diabetes based 
on HbA1c levels ≥6.5%, increasing the prevalence of diabetes 
in the study cohort to 72% (n=2 070). Twenty-eight percent 
(n=586) had diabetic nephropathy (estimated glomerular filtra-
tion rate of <60mL/min/1.73m2), while 18% (n =363) presented 
with diabetic retinopathy. 
The median (interquartile range) admission blood glucose and 
HbA1c levels were 7.8 (5.8 - 13.1)mmol/l and 6.9 (6.0% - 9.0%), 
respectively. The majority of patients were on optimal medical 
therapy at hospital discharge. All patients in hospital with 
hyperglycaemia were treated with an insulin-based regime to 
try to maintain blood glucose levels less than 10mmol/l and 
hypoglycaemia was strictly avoided. Following discharge, 56% 
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TABLE II continued: Baseline characteristics & outcomes of patients according to admission blood glucose.
Blood glucose
Characteristics
Low
<7.8mmol/l
n=1 424 (49%)
Medium
7.8 - 10.9mmol/l
n=456 (16%)
High
≥11mmol/l
n=998 (35%)
p-value
Biochemical data 
Hemoglobin (g/dl) 14.2 (13 - 15.4) 13.6 (12.1 - 15.1) 13.6 (12.1 - 15.3) <0.001
HbA1c (%)(n=2 304) 6.3 (5.8 - 7.8) 7.4 (6.2 - 9) 8.2 (6.4 - 10) <0.001
HbA1c ≥6.5 n (col%) 510/1 121 (46) 246/359 (69) 613/824 (74) <0.001
Creatinine (μmol/L) 92 (80 - 108) 94 (78 - 114) 93 (76 - 117)   0.810
Total cholesterol (mmol/l) 5.16 (4.41 - 5.96) 5.27 (4.42 - 6.07) 5.23 (4.44 - 6.1)   0.142
LDL cholesterol (mmol/l) 3.34 (2.65 - 4.05) 3.25 (2.60 - 4.07) 3.26 (2.54 - 3.99)   0.191
HDL cholesterol (mmol/l) 0.95 (0.79 - 1.14) 0.93 (0.80 - 1.12) 0.94 (0.8 - 1.14)   0.661
Triglycerides (mmol/l) 1.53 (1.08 - 2.22) 1.76 (1.28 - 2.55) 1.85 (1.28 - 2.78) <0.001
Peak Troponin T (ng/ml) 2.25 (0.55 - 5.37) 1.78 (0.39 - 4.89) 2.23 (0.67 - 5.21)   0.087
IQR = Interquartile Range.
   
FIGURE 1: Multivariable logistic regression analysis of clinical and laboratory parameters associated with mortality.
10 2 3 4 5 6 7 8 9 10 11
Odds ratio (95% CI)
Cerebrovascular accident
Shock
Complete heart block
Ventricular arrhythmia
High blood glucose
Recurrence of infarction
Cardiac failure
Age ≥65 years
Atrial fibrillation
High creatinine
Killips classification (2 or more)
Supraventricular tachycardia
Medium blood glucose
High pulse
Hypertension
Male
Anaemia
Diabetes
OR (95% CI)
4.9 (2.5 - 9.8)
4.6 (3.0 - 7.1)
2.4 (1.3 - 4.7)
2.3 (1.4 - 3.9)
2.0 (1.3 - 3.0)
2.0 (1.3 - 3.2)
2.0 (1.3 - 3.0)
1.8 (1.3 - 2.5)
1.8 (0.9 - 3.4)
1.8 (1.3 - 2.4)
1.7 (1.1 - 2.6)
1.5 (0.4 - 5.5)
1.5 (1.0 - 2.4)
1.2 (0.9 - 1.6)
1.1 (0.8 - 1.5)
1.0 (0.7 - 1.4)
1.0 (0.7 - 1.5)
0.7 (0.5 - 1.0)
p-value
<0.001
<0.001
0.008
0.001
0.001
0.003
0.002
<0.001
0.075
<0.001
0.027
0.503
0.065
0.36
0.735
0.907
0.937
0.077
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were on oral hypoglycaemic agents (OHA) that included either 
metformin, sulphonylureas or both, insulin alone (25%), or a 
combination of insulin and OHA (19%).
Baseline characteristics and clinical outcomes of study partici-
pants according to admission blood glucose categories are sum-
marised in Table II. The majority of patients were in the low 
admission blood glucose group (49%), while 16% presented in 
the medium admission blood glucose group and 35% in the 
high admission blood glucose group. A significantly greater 
number of male patients presented in the low admission blood 
glucose group (77%, p<0.001) when compared to their female 
counterparts who were more likely to have higher admission 
blood glucose values (p<0.001). Obese patients as assessed 
by BMI and those with increased visceral obesity as determined 
by abdominal waist circumference measurements were also 
found to have significantly higher admission blood glucose levels 
(p=0.002 and p<0.001, respectively). As expected, diabetic 
patients had higher admission blood glucose levels (high group 
96%, medium group 76% compared to the low group 27%, 
p<0.001). A similar trend was observed for patients with 
hypertension (p<0.001) and for those with a family history of 
diabetes (p<0.001) and hypertension (p<0.001). Patients with 
high admission blood glucose levels had lower ejection fraction 
on echocardiography (p<0.001), abnormal Killip class (p<0.001), 
decreased median serum haemoglobin (13.6 g/dL, [IQR 12.1 - 
15.3], p<0.001), hypertriglyceridaemia (1.85mmol/l, [IQR 1.28 - 
2.78], p<0.001) and higher HbA1c levels (8.2%, [IQR 6.4 - 10], 
p<0.001). 
Analysis of MACE showed that the highest prevalence of 
MACE was observed in the high admission blood glucose group 
(42%) when compared to either the medium group (39%) or 
the low admission blood glucose group (26%), p<0.001. This 
was particularly evident for cardiogenic shock (p<0.001), car-
diac failure (p<0.001) and death (p<0.001). No significant 
correlation was seen between the 3 study groups for angio-
graphic severity of disease and coronary revascularisation. 
Similarly, no significant association was found for the 38% 
(n=871) of STEMI patients who received thrombolysis.
A summary of the multivariable analysis for identifying factors 
associated with mortality by logistic regression analysis is shown 
in Figure 1. In addition to cerebrovascular accidents (p<0.001), 
cardiogenic shock (p<0.01), complete heart block (p=0.008), 
ventricular arrhythmias (p=0,001), recurrence of infarction 
(p=0.003), cardiac failure (p=0.002), age ≥65 years (p<0.001), 
high creatinine (p<0.001) and Killip class ≥2 (p=0.027), patients 
with high admission blood glucose levels also conferred a 
significant increased odds of mortality (p=0.001).
We plotted the AUC with identified optimal cut-off value of 
admission blood glucose for predicting mortality in patients 
with AMI (Figure 2). These analyses suggested that optimal 
blood glucose cut-off identified in this cohort (admission blood 
 
FIGURE 3: Admission blood glucose vs. major adverse 
cardiovascular events. A blood glucose cut-off of 8.1 was 
found to be optimal for the prediction of major adverse cardiac 
events. Area under receiver operating characteristic curve 
(AUC) = 0.61, sensitivity = 0.60, specifi city = 0.57, positive 
predictive value = 0.41, negative predictive value = 0.74.
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FIGURE 2: Admission blood glucose vs. mortality. A 
blood glucose cut-off of 8.5 was found to be optimal for the 
prediction of mortality. Area under receiver operating charac-
teristic curve (AUC) = 0.63, sensitivity = 0.67, specifi city = 0.56, 
positive predictive value = 0.13, negative predictive value =  0.94.
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glucose of 8.5mmol/l) had modest predictive capability for 
mortality with an AUC of 0.63 and corresponding sensitivity 
and specificity of 0.67 and 0.56, respectively. Similarly, the 
optimal blood glucose cut-off identified in this study for MACE 
(admission blood glucose of 8.1mmol/l) also displayed modest 
predictive capability with an AUC of 0.61, and corresponding 
sensitivity of 0.60 and specificity 0.57 (Figure 3).
DISCUSSION
Individuals with diabetes mellitus are at increased risk for the 
development of AMI(12,13) and diabetes is now considered a 
coronary risk equivalent by the National Cholesterol Education 
Programme.(14) The current study confirms these findings with 
the prevalence of self-reported diabetes being present in 59% 
of patients with AMI. An additional 377 patients were diag-
nosed with diabetes based on HbA1c levels, suggesting that 
the more accurate prevalence of diabetes in the study cohort 
was 72%. Given the widespread use of HbA1c in the diagnosis 
and management of patients with diabetes, we believe that 
the use of HbA1c in the majority of patients is a key strength 
of our study. The presence of elevated levels of HbA1c levels 
in these patients makes stress hyperglycaemia a less likely diag-
nosis, indicating that the metabolic abnormality preceded the 
infarction. These results concur with a recent local study which 
compared different diagnostic criteria for the detection of 
undiagnosed diabetes in 896 acute myocardial infarction 
patients (data unpublished). Of interest is that using HbA1c 
criteria, 32% of patients were diagnosed with diabetes while 
47% were diagnosed with pre-diabetes, highlighting the 
increased prevalence of diabetes in this geographical region. 
Our findings support the importance of screening for glucose 
abnormalities in patients hospitalised for AMI to strengthen 
secondary preventative efforts (including medical and lifestyle 
interventions) in a high-risk patient population. 
Patients in the study also presented with multiple conventional 
risk factors such as smoking, hypertension, dyslipidemia, obesity, 
and a family history of vascular disorders, which may also 
possibly have contributed to the occurrence of AMI. Therefore, 
a comprehensive risk factor intervention strategy is required 
over and above strict glycaemic control to decrease the risk of 
complications following an AMI.
Several studies have reported a positive association between 
higher glucose concentrations, adverse clinical outcomes and 
mortality in patients with AMI both during hospital admission 
and post-discharge.(15,16) Although the mechanisms by which 
hyperglycaemia cause harmful effects in patients with AMI are 
unclear, it has been suggested that a wide variety of patho-
physiological changes are involved. These include volume 
depletion, increased free fatty acid production, decreased nitric 
oxide availability, increased coagulopathy and atherogenesis, 
endothelial dysfunction and increased circulating inflammatory 
cytokines.(17-19) Our findings are in agreement with previous 
reports. Thirty-five percent of patients presented in the high 
admission blood glucose group and this group experienced 
a significantly greater number of MACE when compared to 
either the medium or low admission blood glucose groups 
(p<0.001). Of note, is that a significantly greater proportion of 
diabetic patients and those with the highest HbA1c values 
were found in the high admission blood glucose group, 
indicating that they had poor glycaemic control prior to their 
infarction. Patients in the high admission blood glucose group 
were significantly more likely to be hypertensive, obese, and 
have a worse Killip class.
Cardiac failure, cardiogenic shock and death were the most 
common adverse events observed in the high admission blood 
glucose group when compared to the lower admission blood 
glucose groups. These results concur with an analysis of 15 
different trials that addressed the prognostic significance of 
admission blood glucose concentrations in patients with AMI.(20) 
The pathogenesis of heart failure in diabetes is multifactorial, 
but can be largely attributable to ischaemic heart disease, hyper-
tension, diabetic cardiomyopathy and extracellular fluid volume 
expansion.(21,22) More importantly, cardiac metabolism is altered 
in the presence of heart failure due to decreased mitochon-
drial function as a result of the accumulation of medium and 
long chain acyl-carnitine, increased ketone metabolism and 
the accumulation of lactate and branch chain amino acids.(23) 
Patients with diabetes, therefore, are at increased risk for the 
development of heart failure and the prevention of heart failure 
is becoming a major emerging research and treatment goal 
such as the discovery of the sodium-glucose co-transporter 2 
(SGLT2) inhibitors for the treatment of diabetes and co-
existent heart failure.(24) Thus, our findings provide a contem-
porary picture in a South African cohort of patients suggesting 
that elevated admission blood glucose levels are a prognostic 
marker for in-hospital and short-term adverse clinical outcomes 
in patients with AMI.
Furthermore, following multivariable logistic regression analyses 
of clinical and laboratory parameters associated with mortality, 
in addition to cerebrovascular accidents, cardiogenic shock, 
complete heart block, ventricular arrhythmias, recurrence of 
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infarction, cardiac failure age ≥65 years, high creatinine and Killip 
class ≥2, high admission blood glucose also conferred a signi-
ficant increased odds of mortality. 
In addition to the admission value, a graded relationship has 
been found between increasing blood glucose levels and MACE. 
However, the optimal glucose cut-off value for the prediction 
of poor outcomes has not been determined. We also investi-
gated the optimal cut-off admission blood glucose value as 
determined via a ROC curve for predicting in-hospital and 6 
months’ mortality in patients with AMI. The optimal cut-off 
point was an admission blood glucose value of 8.5mmol/l, 
which has only modest capability for predicting mortality. 
Similarly, the optimal cut-off point for MACE was an admission 
blood glucose value of 8.1mmol/l, which also displayed modest 
predictive capability. Hence, these cut-off values are only 
exploratory and further studies are required before they may 
serve as indicators of clinical reference for secondary preven-
tion for improving the prognosis after AMI. We are unaware of 
any large studies in South Africa that examined the prevalence 
and predictive value of admission blood glucose in patients 
presenting with AMI and our study may provide important 
epidemiological insight into elevated admission blood glucose 
as a risk factor for MACE. Although HbA1c, which reflects 
metabolic and glycaemic control, has been shown to be a 
significant predictor of MACE after AMI,(25) elevated admission 
blood glucose may serve as a cost-effective and easily obtainable 
alternate prognostic marker.
LIMITATIONS
Several potential limitations need acknowledgement. First, this 
was a retrospective observational study with few variables 
having missing data, which may have caused selection bias. This 
shortcoming was minimised by using standardised methods for 
data collection, while the large study population allowed for 
greater statistical power. Second, the follow-up period of the 
patients was only 6 months; thus, it is necessary to investigate 
the longer-term relationship between admission blood glucose 
and MACE. Third, although we reveal that elevated admission 
blood glucose was associated with unfavorable in-hospital and 
6-month outcome, the effects of treating hyperglycaemia after 
admission were not assessed. Finally, 62% of patients with 
STEMI did not receive thrombolytic therapy because of late 
presentation or standard contraindications, while only 38% of 
patients underwent coronary angiographic studies, with no 
patients receiving primary PCI according to timeline-based 
guidelines. Therefore, these data should be interpreted with 
caution, particularly with respect to the various MACE out-
comes observed. This is due to the fact that patients are 
referred to another hospital with long waiting lists for cardiac 
catheterisation, and a large number of them declined inter-
vention or did not have coronary angiograms performed 
because of other co-morbidities.
CONCLUSIONS
The findings from the present study show that patients have 
multiple risk factors for AMI with diabetes playing a central role. 
Elevated admission blood glucose in AMI patients is an 
important indicator for in-hospital and short-term MACE, with 
a graded increase in the risk of MACE demonstrated with 
increasing levels of admission blood glucose. Although the 
optimal blood glucose target in AMI patients with hypergly-
caemia is uncertain, the cut-off admission blood glucose value 
for predicting MACE and mortality in our study has only modest 
predictability and further research is required to improve the 
performance of these measures for routine clinical use.
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